CT071 for high-risk newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been newly diagnosed with multiple myeloma.
- Your myeloma has high-risk features, such as specific genetic changes, advanced stage, or soft tissue tumors.
- You have measurable disease, meaning a certain level of M-protein in your blood or urine.
- You have not had prior treatment for multiple myeloma, except for up to 2 cycles of a common combination therapy (bortezomib, lenalidomide, dexamethasone).
- Your overall health is fairly good (ECOG score 0-2) and your organ function, like kidney and liver, is within acceptable ranges.
- You are willing to use effective contraception if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This study tests a new treatment called CT103A CAR-T therapy for people newly diagnosed with high-risk multiple myeloma. It uses your own immune cells to attack the cancer cells, and may help control the disease even when it's aggressive.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.